News
-
-
-
-
-
-
PRESS RELEASE
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
Kuros Biosciences AG reports significant growth in direct MagnetOs sales (163%) and total medical device sales (153%) in 2023. Positive EBITDA achieved. Plans for continued sales growth and profitability in 2024 -
-
PRESS RELEASE
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
Kuros Biosciences to report full-year financial results for 2023 and provide corporate update on March 13, 2024, with a conference call and webcast scheduled. Company overview and contact information included -
PRESS RELEASE
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
Kuros Biosciences to present at the CG 2024 Musculoskeletal Conference in San Francisco, discussing its MagnetOs portfolio of products for spinal fusion. CEO Chris Fair and other executives will attend, with a replay available for 90 days. Kuros Biosciences is a leader in next generation bone graft technologies -
PRESS RELEASE
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
Kuros Biosciences receives US FDA 510K clearance for MagnetOs Granules for interbody use and regulatory clearance in New Zealand. The company expands its international presence with an exclusive distribution agreement, extending the MagnetOs portfolio and bringing an advanced bone graft technology to the local medical community
-
LaMar’s Donuts Celebrates National Donut Day 2024
-
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
-
abrdn Income Credit Strategies Fund Announces Update and Tentative Closing Date for Acquisition of Assets From First Trust High Income Long/Short Fund
-
Electric Royalties Announces Interest Conversion Under Convertible Credit Facility
-
Pfister Faucets' American Plumber Stories Docuseries Wins Three Telly Awards
-
EQS-Adhoc: Vectron Systems AG: Vectron enters into Business Combination Agreement, resolves 10% capital increase without subscription rights of the shareholders and supports voluntary public acqusition offer
-
CPI PROPERTY GROUP publishes financial results for the first quarter of 2024
-
Leclanché SA: Publishes its Annual Report 2023 and Non-financial ESG Report
-
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
-
Molten Ventures Plc: HOL-Holding(s) in Company
-
ACCOR - Description of own share buyback programme
-
ACCOR - Press release following the 2024 general meeting
-
Capital increase through exercise of subscription rights
-
NFL BIOSCIENCES: RESULTS OF THE COMBINED GENERAL MEETING OF MAY 30, 2024
-
Thales has completed the sale of its Ground Transportation Systems business